Binkow & Goldberg LLP announces that it is investigating
potential claims on behalf of investors of Cleveland
BioLabs, Inc. ("Cleveland BioLabs" or the "Company") (NASDAQ: CBLI)
concerning possible violations of federal securities laws. The
investigation is focused on certain statements issued by Cleveland
BioLabs concerning the Company's business and financial prospects.
Please contact us at (212) 682-5340, Toll-Free at (888) 773-9224, or at firstname.lastname@example.org
to discuss this matter. If you inquire by email please include your
mailing address, telephone number and number of shares purchased.
Cleveland BioLabs is a clinical-stage biotechnology company, engaged in
the research, development and commercialization of products that have
the potential to treat cancer, reduce death from total body irradiation
and counteract the genotoxic effects of radio and chemotherapies for
oncology patients. The investigation focuses on certain statements
contained in the Registration Statement issued in connection with the
Company's January 14, 2014, public securities offering, related to
funding from the Biomedical Advanced Research Development Authority.
On January 23, 2014, shortly after the offering, Cleveland BioLabs
announced that the Biomedical Advanced Research Development Authority
"terminated negotiations related to the company's proposal for further
development of Entolimod as a medical radiation countermeasure."
If you purchased Cleveland BioLabs securities pursuant to the January
14, 2014, public offering, if you have information or would like to
learn more about these claims, or if you have any questions concerning
this announcement or your rights or interests with respect to these
matters, please contact Michael
Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century
Park East, Suite 2100, Los Angeles, California 90067, Toll-Free at (888)
773-9224, or contact Gregory
Linkh, Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd
Street, Suite 2920, New York, New York 10168, at (212) 682-5340, by
e-mail to email@example.com,
or visit our website at http://www.glancylaw.com.
If you inquire by email, please include your mailing address, telephone
number and number of shares purchased.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
[ Back To NFVZone's Homepage ]